Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esflurbiprofen topical system in contusions
NCT06871046Phase 3Completed
- Sponsor
- Teikoku Seiyaku Co., Ltd.
- Start
- Feb 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of esflurbiprofen in contusion, sponsored by Teikoku Seiyaku Co., Ltd. Primary endpoint: Adverse Events. Started Feb 2025; status: completed.
02
Drugs
esflurbiprofen
03
Conditions
contusion
Beyond the preview
Go deeper on NCT06871046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06871046.